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Liquid Tissue™: proteomic profiling of  
formalin-fixed tissues
DaRue A. Prieto1, Brian L. Hood1, Marlene M. Darfler2, Thomas G. Guiel2, David A. Lucas1,  
Thomas P. Conrads1, Timothy D. Veenstra1, and David B. Krizman2
1SAIC-Frederick, Inc., National Cancer Institute, Frederick and 2Expression Pathology, Inc., Gaithersburg, MD, USA
Identification and quantitation of candidate biomarker proteins in large numbers of individual tissues is required to validate specific 
proteins, or panels of proteins, for clinical use as diagnostic, prognostic, toxicological, or therapeutic markers. Mass spectrometry (MS) 
provides an exciting analytical methodology for this purpose. Liquid Tissue™ MS protein preparation allows researchers to utilize the vast, 
already existing, collections of formalin-fixed paraffin-embedded (FFPE) tissues for the procurement of peptides and the analysis across a 
variety of MS platforms.
BioTechniques 38:S32-S35 (June 2005)
INTRODUCTION
Proteomic profiling of diseased and normal tissue by mass 
spectrometry (MS) is at an early stage, yet it promises to decipher 
proteomic complexities of the tissue microenvironment and to 
deliver biomarker information with appropriate pathologic and histo-
logic relevance. Mass spectrometric profiling of the complex cellular 
proteome obtained from diseased tissue has previously been 
demonstrated with frozen cancer tissue (1–5). However, the use of 
frozen tissue for such analysis is problematic for several reasons. 
These difficulties include collecting sufficient tissue samples for large 
studies (especially human tissue), the need to design the collection 
of tissues in a prospective manner, the cumbersome nature of first 
processing then analyzing frozen tissue, and the effort/expense of 
storing such tissue on a long-term basis.
In contrast, formalin fixation of tissue is a routine process that 
provides an easily stored archive of tissue that is pathologically 
well-defined. Extensive archives of animal and human fixed tissue 
have been collected, assembled, and stored at room temperature 
for decades; the majority of which contain associated clinical and 
experimental information representing an extremely valuable 
untapped reservoir of potential biomarkers. However, current 
methods of proteomic analysis for formalin-fixed tissue are limited 
to immunohistochemistry (IHC) (6,7). This methodological limitation 
is due to the protein cross-linking properties of formalin, which 
preserves the proteins but renders them insoluble. This process 
makes the proteins within these samples incompatible with many 
of the discovery tools used in proteomics today, leaving these fixed 
archival tissue collections inaccessible for further exploration of 
biological knowledge (8–12). 
Expression Pathology has developed a patent pending process, 
termed Liquid Tissue™, for the extraction of peptides directly 
from formalin-fixed tissue. This report demonstrates the analysis 
of peptides obtained from formalin-fixed tissue utilizing the Liquid 
Tissue process across a variety of MS platforms, including microcap-
illary reversed-phase liquid chromatography (μRPLC) tandem mass 
spectrometry (MS/MS), matrix-assisted laser desorption ionization 
(MALDI) tandem time-of-flight (TOF/TOF), and surface-enhanced 
laser desorption ionization time-of-flight (SELDI-TOF). Results from 
SELDI-TOF MS analysis reveal tissue-based patterns of protein 
expression on a variety of chromatographic chip surfaces, while 
multiple protein identifications were obtained from μRPLC-MS/MS, 
all from a single Liquid Tissue extract. These results demonstrate 
that the Liquid Tissue methodology provides the ability to unlock the 
proteome of the world’s vast reservoir of archived tissue for large-
scale discovery and validation of biomarkers to improve disease 
diagnosis and therapy. 
MATERIALS AND METHODS
Chemicals and Reagents
Formic acid (HCOOH) and trifluoroacetic acid (TFA) were 
purchased from Sigma (St. Louis, MO, USA). High-performance 
liquid chromatography (HPLC)-grade acetonitrile (ACN; CH3CN) 
was obtained from EMD Chemicals (Gibbstown, NJ, USA). All 
buffers and reagents were used as supplied from the manufacturer 
and prepared in double-distilled water using a NANOPure Diamond® 
water system (Barnstead International, Dubuque, IA, USA). The 
Liquid Tissue MS Protein Prep kit was from Expression Pathology 
(Gaithersburg, MD, USA).
Tissue Processing and Peptide Extraction
A formalin-fixed paraffin-embedded (FFPE) colon cancer tissue 
with well-defined adenocarcinoma was analyzed by standard histo-
logical methods in order to identify a cancerous region consisting 
of at least 70% cancerous epithelium with little to no observable 
lymphocytic infiltration. A 5 μm-thick section was cut, placed on a 
glass slide, and stained with hematoxylin and eosin (H&E) for identi-
fication of the cancerous region. A 10 μm-thick section was placed 
on a second slide for tissue dissection and peptide procurement. 
Paraffin was removed by treatment in SubX organic solvent 
(Surgipath Medical Industries, Richmond, IL, USA) twice for 5 min, 
followed by tissue rehydration through multiple graded ethanol 
solutions and distilled water. The cancerous region of interest was 
identified microscopically using the H&E-stained region to locate 
the cells for macrodissection with a sterile 30-gauge hypodermic 
needle in the rehydrated tissue section. The collected sample, 
approximately 120,000 cells, was placed into a 1.5-mL low-binding 
microcentrifuge tube containing 40 μL Liquid Tissue buffer. 
Peptides were extracted utilizing the Liquid Tissue MS Protein 
Prep kit according to the manufacturer’s protocol. Briefly, the cellular 
material, suspended in the Liquid Tissue buffer, was incubated at 
95°C for 90 min, then cooled on ice for 3 min. Trypsin was added 
(approximately 15–18 U) followed by incubation at 37°C overnight. 
Dithiothreitol was added to a final concentration of 10 mM, and the 
samples were heated for 5 min at 95°C. The Liquid Tissue digestate 
was stored at -20°C until analysis. 
Nanoflow RPLC-MS/MS Analysis
μRPLC-MS/MS was performed using an Agilent 1100 capillary 
LC system (Agilent Technologies, Palo Alto, CA, USA) coupled 
online to a linear ion trap (LIT) mass spectrometer (LTQ; Thermo 
Electron, Waltham, MA, USA). Separations were performed using 
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75 μm inner diameter (i.d.) × 360 μm outer diameter (o.d.) × 10 
cm long fused silica capillary columns (Polymicro Technologies, 
Phoenix, AZ, USA) that were slurry packed in-house with 3 μm, 300 
Å pore size C-18 silica-bonded stationary phase (Vydac, Hysperia, 
CA, USA). An aliquot of the Liquid Tissue extract (corresponding 
to approximately 6000 cells) was desalted using C-18 ZipTip™ 
microcolumns (Millipore, Billerica, MA, USA), lyophilized, and resus-
pended in a minimal amount of 0.1% TFA prior to μRPLC-MS/MS 
analysis. Following sample injection, the column was washed for 20 
min with 98% mobile phase A (0.1% formic acid in water) at a flow 
rate of 0.5 μL/min. Peptides were eluted using a linear gradient of 
2% mobile phase B (0.1% formic acid in ACN) to 42% solvent B in 
40 min, then to 98% B in an additional 28 min, all at a constant flow 
rate of 250 nL/min. 
The LIT-MS was operated in data-dependent MS/MS mode, 
in which each full MS scan was followed by five MS/MS scans, 
respectively, where the five most abundant peptide molecular 
ions were selected for collision-induced dissociation (CID) using a 
normalized collision energy of 35%. Dynamic exclusion was utilized 
to minimize redundant selection of peptides previously selected for 
CID. The heated capillary temperature and electrospray voltage 
were set at 160°C and 1.5 kV, respectively. Data were collected 
over a broad mass-to-charge (m/z) precursor ion selection scan 
range of 400–2000.
Tandem mass spectra were searched against the UniProt 
human proteomic database (01-04-05 release) from the European 
Bioinformatics Institute (www.ebi.ac.uk/integr8) using SEQUEST® 
(Thermo Electron). For a fully tryptic peptide to be considered 
legitimately identified, it had to achieve stringent charge state and 
proteolytic cleavage-dependent cross correlation (Xcorr) scores 
of 1.9 for [M+H]1+, 2.2 for [M+2H]2+, and 3.1 for [M+3H]3+, and a 
minimum delta correlation (∆Cn) of 0.08. SEQUEST results were 
further filtered using software developed in-house to determine 
unique peptides and proteins.
SELDI-TOF Analysis
In preparation for the SELDI-TOF analysis, 25 μL Liquid Tissue 
colon cancer extract (corresponding to approximately 75,000 cells) 
were lyophilized and resuspended in 10 μL binding/wash buffer 
[phosphate-buffered saline (PBS), pH 7.4, containing 0.1% Triton® 
X-100]. The sample was then applied sequentially to the different 
SELDI surfaces in the following manner.
The immobilized metal affinity capture (IMAC3) ProteinChip® 
Array (Ciphergen Biosystems, Palo Alto, CA, USA) was loaded 
with copper (100 mM CuSO4), washed with HPLC-grade water, and 
incubated with 50 mM sodium acetate, pH 4.0. Following a brief 
HPLC-grade water wash, the array was then pre-equilibrated in 
binding/wash buffer. Sample was applied to the array surface using 
a ProteinChip Bioprocessor (Ciphergen Biosystems) and incubated 
for 2 h at ambient temperature with gentle agitation. Sample was 
aspirated from the array surface and stored at 4°C until further use. 
The array was washed twice with binding/wash buffer, followed by 
two final 5 mM Tris, pH 8.0, washes. The ProteinChip Bioprocessor 
was subsequently removed, and the array was air-dried prior to 
analysis.
The weak cation exchange (WCX2) ProteinChip Array was 
pretreated with 10 mM HCL and washed with HPLC-grade water 
followed by pre-equilibration in binding/wash buffer (50 mM sodium 
acetate, pH 4.5, containing 0.1% Triton X-100). Sample obtained 
from the IMAC3 ProteinChip Array surface was lyophilized and 
resuspended in 10 μL WCX2 binding/wash buffer. Sample was 
applied to the WCX2 array surface using a ProteinChip Bioprocessor 
and incubated for 2 h at ambient temperature with gentle agitation. 
Sample was aspirated from the array surface and stored at 4°C until 
further use. The array was washed twice with binding/wash buffer, 
followed by two final HPLC-grade water washes. The ProteinChip 
Bioprocessor was subsequently removed, and the array air-dried 
prior to analysis.
The strong anion exchange (SAX2) ProteinChip Array was pre-
equilibrated with SAX2 binding/wash buffer (50 mM Tris, pH 8.0, 
containing 0.1% Triton X-100). Sample obtained from the WCX2 
ProteinChip Array surface was lyophilized and resuspended in 10 
μL SAX2 binding/wash buffer. Sample was applied to the SAX2 
array surface using a ProteinChip Bioprocessor and incubated for 
2 h at ambient temperature with gentle agitation. The array was 
washed twice with binding/wash buffer, followed by two final 5 mM 
Tris, pH 8.0, washes. The ProteinChip Bioprocessor was subse-
quently removed, and the array air-dried prior to analysis. 
For the gold ProteinChip Array surface, 5 μL liquid tissue 
colon cancer extract (approximately 15,000 cells) were lyophilized 
and resuspended in 3 μL HPLC-grade water. One microliter of a 
saturated sinapinic acid solution in 50% ACN, 0.5% TFA was mixed 
with the sample and directly spotted onto the gold array surface. 
A total of 1 μL of a saturated sinapinic acid solution in 50% 
ACN, 0.5% TFA was added to each spot of the IMAC3, WCX2, 
and SAX2 ProteinChip Arrays. Data acquisition settings were 
dependent upon the ProteinChip array type used: laser intensities 
of 215–220, detector sensitivities of 8–10, and a molecular mass 
range 0–100,000 Da, with 130 averaged shots per spectrum. Data 
were collected and analyzed using ProteinChip software version 3.2 
(Ciphergen Biosystems).
MALDI-TOF/TOF Analysis
MALDI-TOF/TOF analysis was performed on a Voyager 4700 
MALDI-TOF/TOF™ mass spectrometer (Applied Biosystems, 
Foster City, CA, USA). Sample was co-crystallized with an equiv-
alent amount of α-cyano-4-hydroxycinnamic acid in 50% ACN, 
0.1% TFA, and spotted directly on a stainless steel MALDI target 
plate. Data was collected at a laser frequency of 200 Hz, and the 
collision energy for CID was 1 keV (air was used as collision gas). 
Post-acquisition baseline correction and smoothing was carried out 
using software provided with the instrument. 
Figure 1. Microcapillary reversed-phase liquid chromatography tandem 
mass spectrometry (µRPLC-MS/MS) analysis of proteins extracted from 
formalin-fixed colon cancer tissue. The efficiency of extracting proteins 
from formalin-fixed colon cancer tissue using the Liquid Tissue method is 
exemplified by the complexity of the resultant MS base peak chromatogram. 
Over 600 peptides were identified from this µRPLC-MS/MS analysis of 
formalin-fixed paraffin-embedded (FFPE) colon cancer tissue. m/z, mass-to-
charge ratio.
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RESULTS AND DISCUSSION
Even though the complexity makes qualitative and quantitative 
analysis of a cell’s proteome difficult at best, observations carried 
out at the protein level are inherently attractive because of the cause 
and effect relationship between protein expression and biological 
function. Informative pathologic context and relevance makes tissue-
based studies important for linking proteins directly to biological and 
disease processes. Fresh frozen tissue is difficult to obtain in large 
numbers, expensive to store, and difficult to process, whereas large 
collections of well-defined FFPE tissue with clinical history (and 
often patient outcome) are readily available. Unfortunately, effective 
and routine analysis of proteins in formalin-fixed tissue has been 
limited to IHC. This limitation is due to the chemical cross-linking 
properties of the common fixative reagent formalin, preventing 
standard protein preparation methodologies from extracting soluble 
protein from fixed tissue. Samples processed using the Liquid 
Tissue methodology allow for the proteomic analysis of formalin-
fixed tissue not previously attainable. 
One analytical method that can be used in conjunction with Liquid 
Tissue protein extraction is MS. Multidimensional LC separation 
methods when combined with MS provide sufficient separation and 
resolution to resolve, detect, and identify multiple proteins simulta-
neously, while providing broad proteome coverage of a single Liquid 
Tissue protein preparation. In addition, MS pattern determination 
utilizing SELDI technology can be employed to develop proteomic 
profiles characterizing individual Liquid Tissue protein preparations.
A colon cancer Liquid Tissue extract was prepared from a FFPE 
tissue and analyzed on numerous MS platforms to demonstrate 
both the practicality and versatility of this approach. Microcapillary 
RPLC-MS/MS analysis of the peptides obtained from this colon 
cancer tissue extract resulted in the detection of thousands of 
species as shown by the base peak chromatogram provided in 
Figure 1. A single injection of a diluted extract resulted in the actual 
identification of 629 unique, fully tryptic peptides representing over 
350 unique proteins. Interestingly, a 20-fold lower injection volume 
yielded almost the same results: 501 unique fully tryptic peptides 
corresponding to 289 unique proteins. In each case, nearly 40% of 
the unique proteins were identified by two or more unique peptides. 
Many of the proteins identified in this study by multiple unique 
peptides have previously been shown to have differential expression 
levels in a comparison of normal mucosa and colorectal cancer 
tissue, including annexin V, α-tropomyosin, and triosephosphate 
isomerase (13).  
While individual protein identification is important for correlating 
potential expression levels with defined histological states, the 
ability to evaluate proteomic patterns in various samples also plays 
a significant role in biomarker discovery. Although still in its infancy, 
proteomic pattern diagnostics using SELDI-TOF MS holds great 
promise as a diagnostic tool. This technique uses the principles of 
retentate chromatography to selectively bind biological samples 
to the ProteinChip Array surface. Nonspecifically bound peptides, 
proteins, salts, and other interfering compounds are washed away. 
The peptides/proteins retained on the array surface are then 
analyzed by TOF-MS after applying matrix to the sample. This 
technique has been successfully employed for the early detection 
of numerous cancers, including ovarian (14), prostate (15), cervical 
(16), and pancreatic (17) cancers. SELDI-TOF MS of the colon 
cancer tissue extract revealed complex peptide spectra on a variety 
of chromatographic surfaces (Figure 2). Spectra obtained on the 
WCX2 and SAX2 array surfaces are even more interesting, since 
sample limitation required application of the same tissue extract 
consecutively on these surfaces. For example, after the sample 
was applied to the IMAC3 chip, the solution of peptides that did not 
Figure 2. Surface-enhanced laser desorption ionization time-of-flight mass 
spectrometry (SELDI-TOF MS) analysis. An analysis of the Liquid Tissue 
extract was performed using SELDI-TOF MS. Colon cancer tissue extract was 
processed on the following ProteinChip surfaces (top panel): (A) immobi-
lized metal affinity chromatography (IMAC3), (B) strong anion exchange 
(SAX2), (C) weak cation exchange (WCX2), (D) Au Chip. In each case, the 
sample was lyophilized and resuspended in the appropriate binding buffer 
for each chip surface. The sample was processed on the IMAC3 ProteinChip 
array first, followed by WCX2, and then SAX2. The bottom panel shows the 
virtual gel representation of each SELDI-MS spectrum (labeled as in the top 
panel). The Gold ProteinChip was processed separately using an aliquot of 
the original sample. m/z, mass-to-charge ratio.


































Figure 3. Matrix-assisted laser desorption ionization tandem time-of-
flight (MALDI-TOF/TOF) analysis of proteins extracted from formalin-
fixed paraffin-embedded (FFPE) colon cancer tissue. Peptides extracted 
from formalin-fixed colon cancer tissue using the Liquid Tissue method 
were analyzed using a Voyager 4700 high-resolution MALDI-TOF/TOF mass 
spectrometer showing a large number of observable peptides, including well-
resolved low-level signals (inset). m/z, mass-to-charge ratio.
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bind to this surface was collected, relyophilized, and then applied to 
the WCX2 chip. Likewise, the solution of peptides that did not bind 
to the WCX2 chip were collected, relyophilized, and applied to the 
SAX2 chip. Even with the loss of peptides bound to the previous 
ProteinChip array type, complex spectra from a single sample 
applied on multiple chromatographic surfaces was still observed. 
The gold ProteinChip surface was used to evaluate the global colon 
cancer Liquid Tissue extract. This approach to proteomic pattern 
analysis offers a convenient alternative when sample is severely 
limited and is insufficient to apply fresh samples to each ProteinChip 
array surface.
As expected, the proteomic profiles of the peptides extracted 
from the colon cancer tissue extract were dependent on the 
chromatographic surface (i.e., IMAC3, WCX2, and SAX2) used. The 
complexity of the spectra, however, is quite high, showing that the 
extraction of peptides from formalin-fixed tissue using Liquid Tissue 
is quite efficient. As has been done primarily for plasma and serum 
samples, these results show that proteomic profiles generated 
from formalin-fixed tissues also have the potential to be coupled 
with SELDI-TOF MS for the identification of biomarkers of specific 
diseases. Studying formalin-fixed tissues has many advantages 
over studying biofluids, in that retrospective samples are easily 
obtained, and issues related to sample collection are not as critical. 
There is an active area of research that is attempting to use 
higher resolution MS platforms to obtain proteomic patterns. To 
meet this demand, we investigated the capability of obtaining 
proteomic profiles of peptides extracted from FFPE tissues using 
a high-resolution MALDI-TOF spectrometer. Peptides extracted 
from a FFPE colon cancer tissue using the Liquid Tissue method 
were spotted onto a target plate, and the spectrum was acquired 
using a Voyager 4700 high-resolution MALDI-TOF/TOF mass 
spectrometer. The resulting spectrum revealed a large number of 
observable peptides as shown in Figure 3. Expansion of a region 
within this spectrum shows that a large number of highly resolved, 
low-level signals are readily detectable using this direct MALDI 
approach (Figure 3, inset). These results show the complexity and 
flexibility of the Liquid Tissue methodology to allow proteome inves-
tigation of peptides extracted from FFPE tissue on a variety of mass 
spectrometry platforms. 
The development of methods to use state-of-the-art proteomic 
discovery tools to analyze FFPE tissue provides an exciting new 
opportunity to identify disease-specific biomarkers in pathologi-
cally defined samples. There are vast archives of formalin-fixed 
tissues, human and animal, spanning every conceivable condition 
(disease, time, treatment, and outcomes), allowing acquisition of the 
necessary numbers of samples to carry out in-depth analyses on a 
disease of interest. 
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